Acid Suppression in Mild-Moderate Laryngomalacia Without GERD: A Randomized Controlled Trial.

ABSTRACT:

Objective

To determine the efficacy of acid suppression therapy (AST) for the treatment of gastroesophageal reflux (GER) and airway symptoms in infants with mild to moderate laryngomalacia.

Methods

From 2020 to 2023, infants ≤ 6 months old with laryngomalacia at a tertiary children's hospital were randomized to famotidine and feeding modifications (AST) or feeding modifications alone (no-AST). Laryngomalacia Airway Symptom Score (LASS) and Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) were completed by guardians. Of 343 patients approached, 257 were excluded due to severe laryngomalacia on LASS, severe GER (I-GERQ-R ≥ 16), prior AST, no laryngomalacia on laryngoscopy, recommendation for supraglottoplasty, and/or other airway anomalies. Twenty-one declined participa

SUBMITTER: Shaffer AD 

PROVIDER: S-EPMC12770870 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature